Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
43
2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
University of California Davis
Sacramento, California, United States
University of California, Davis
Sacramento, California, United States
Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer
Changes in %Ki67 staining cells by immunoperoxidase of paraffin embedded, formalin fixed tissue
Time frame: At time of consent and after hysterectomy (generally about 3 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.